POC(Point of Care) ºÐÀÚÁø´Ü ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¿ëµµº°, ±â¼úº°, °Ë»çÀå¼Òº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2033³â)
Point Of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Application (Infectious Diseases, Oncology, Prenatal Testing, Endocrinology), By Technology, By Test Location, By End-use, By Region, And Segment Forecasts, 2025 - 2033
»óǰÄÚµå : 1790280
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,359,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,764,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,573,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

POC ºÐÀÚÁø´Ü ½ÃÀå °³¿ä

¼¼°è POC(Point-of-Care) ºÐÀÚÁø´Ü ½ÃÀå ±Ô¸ð´Â 2024³â 82¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2033³â¿¡´Â 144¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â 6.52% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ½ÃÀåÀº ȯÀÚ °¡±îÀÌ¿¡¼­ ¼öÇàµÇ´Â ½Å¼ÓÇϰí Á¤È®ÇÑ ºÐÀÚ °Ë»ç¿¡ ÁßÁ¡À» µÎ¾î Àû½Ã¿¡ ÀÓ»óÀû ÆÇ´ÜÀ» ³»¸± ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ç÷§ÆûÀº ƯÈ÷ °¨¿°¼º Áúȯ °¨Áö, È£Èí±â Áúȯ, ¼ºº´ µî ´Ù¾çÇÑ ¿ëµµ·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ƯÈ÷ ÀÚ¿øÀÌ Á¦ÇÑµÈ È¯°æ°ú ÀÀ±Þ ÀÇ·á ȯ°æ¿¡¼­ ºÐ»êÇü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ÀÔ´Ï´Ù. °¨¿°¼º Áúȯ¿¡ ´ëÇÑ ºÎ´ã Áõ°¡¿Í ºü¸¥ ³³±âÀÇ Çʿ伺À¸·Î ÀÎÇØ, Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ºÐÀÚ ±â¼úÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º°øÇÐ, µî¿ÂÁõÆø¹ý, ÈÞ´ë¿ë PCR ½Ã½ºÅÛ µîÀÇ ±â¼ú ¹ßÀüÀ¸·Î ÀÌ·¯ÇÑ Áø´Ü¹ýÀÇ Á¤È®¼º°ú »ç¿ë ÆíÀǼºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Äڷγª19 ÀÌÈÄ ÀÇ·á°èÀÇ ¿ì¼±¼øÀ§·Î ½Å¼ÓÇÑ ´ëÀÀ °Ë»ç°¡ °­Á¶µÇ¸é¼­ ½ÃÀå È®´ë¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, 1Â÷ÀÇ·á ÇöÀå¿¡¼­ÀÇ POC ºÐÀÚÁø´ÜÀº °£´ÜÇÑ Æ÷µµ´ç °Ë»çºÎÅÍ º¹ÀâÇÑ ÀÀ°í °Ë»ç±îÁö ´Ù¾çÇÕ´Ï´Ù. ÀϺΠŬ¸®´Ð¿¡¼­´Â Àü¹®°¡µéÀÌ ±âÁ¸ ½ÇÇè½Ç °Ë»ç¿¡¼­ POC °Ë»ç·Î ÀüȯÇÏ¿© °Ëü Áغñ ¹× ¿î¼Û Áß Áö¿¬À» ÇÇÇÔÀ¸·Î½á Ãß°¡ °Ë»ç°¡ ÇÊ¿äÇÑÁö ¿©ºÎ¸¦ ÆÇ´ÜÇÏ´Â µ¥ °É¸®´Â ½Ã°£À» ´ÜÃàÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. POC ºÐÀÚÁø´ÜÀÇ ¶Ç ´Ù¸¥ ÀåÁ¡Àº ºü¸¥ °á°ú, Àú·ÅÇÑ ºñ¿ë, ÁÁÀº °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. Point of Care ºÐÀÚÁø´Ü »ê¾÷Àº POCTÀÇ ÀÇÇÐÀû, Á¶Á÷Àû ¹®Á¦ ¹× °æÁ¦Àû ÀÌÁ¡ µî ´Ù¾çÇÑ ¹®Á¦¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ¹Ì±¹°ú À¯·´ ±¹°¡¸¦ Áß½ÉÀ¸·Î ÃÖ±Ù ¸î ³â µ¿¾È ±Þ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

³ëÈ­´Â ¿©·¯ ȯ°æÀû ¿äÀΰú À¯ÀüÀû ¿äÀÎÀÇ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ ¿µÇâÀ» ¹ÞÀ¸¸ç, ¾Ï ¹ß»ýÀÇ °¡Àå Áß¿äÇÑ À§Çè ¿äÀÎÀ¸·Î Ư¡Áö¾îÁý´Ï´Ù. ¹Ì±¹ ±¹¸³¾Ï¿¬±¸¼ÒÀÇ Surveillance Epidemiology and End Results(SEER) µ¥ÀÌÅͺ£À̽º¿¡ µû¸£¸é, ¿©¼ºÀÇ 38%, ³²¼ºÀÇ 43%°¡ ÀÏ»ý µ¿¾È ¾Ï¿¡ °É¸± °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ½Å±Ô ¾Ï ȯÀÚÀÇ 3ºÐÀÇ 2°¡ 65¼¼ À̻󿡼­ Áø´ÜµÇ´Â °ÍÀ¸·Î ³ªÅ¸³ª ³ªÀ̰¡ µé¼ö·Ï ¾Ï¿¡ °É¸± È®·üÀÌ ³ô¾ÆÁø´Ù´Â °ÍÀ» ¾Ë ¼ö ÀÖ½À´Ï´Ù. ºÐÀÚÁø´ÜÇÐÀº ¾Ï, °¨¿°¼º Áúȯ, ½ÉÇ÷°ü ÁúȯÀÇ °ü¸®¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡±â ¶§¹®¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. µû¶ó¼­ °øÁß º¸°Ç ¸ð´ÏÅ͸µ ¹× ¹ß°ß¿¡ ÇʼöÀûÀÔ´Ï´Ù. µû¶ó¼­ °í·ÉÀÚ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¶ÇÇÑ, ½ÃÀå °ü°èÀÚµéÀº ½ÃÀå ±âȸ¸¦ Ȱ¿ëÇϱâ À§ÇØ »õ·Î¿î POC °Ë»ç Á¦Ç° °³¹ß¿¡ Áö¼ÓÀûÀ¸·Î ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 2¿ù Huwel Lifesciences´Â ¹ÙÀÌ·¯½º À¯ÇüÀ» °Ë»çÇÏ´Â ÈÞ´ë¿ë RT-PCR ÀåÄ¡¸¦ ¼³°èÇß½À´Ï´Ù. ÀÌ È¸»ç´Â ÀÌ °Ë»ç¿¡ °É¸®´Â ½Ã°£Àº ¾à 30ºÐ Á¤µµÀ̸ç, Ç÷¾×À̳ª À§Àå »ùÇÃÀ» »ç¿ëÇÏ¿© È£Èí±â °¨¿° ¹× ±âŸ °¨¿°À» °¨ÁöÇÏ´Â µ¥ »ç¿ëÇÒ ¼ö ÀÖ´Ù°í ÁÖÀåÇÕ´Ï´Ù. ¶ÇÇÑ, 2023³â 4¿ù, Curative, Inc.´Â Sensible DiagnosticsÀÇ ½ºÇÉ¿ÀÇÁ¸¦ ¹ßÇ¥ÇÏ¿© 10ºÐ À̳»¿¡ ³ôÀº Á¤È®µµ·Î °á°ú¸¦ Á¦°øÇÏ´Â »õ·Î¿î POC PCR °Ë»ç Ç÷§ÆûÀÇ »ó¿ëÈ­¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ±â¼ú ºñÁî´Ï½º ºÐ¼®

Á¦5Àå ¿ëµµ ºñÁî´Ï½º ºÐ¼®

Á¦6Àå °Ë»çÀå¼Ò ºñÁî´Ï½º ºÐ¼®

Á¦7Àå ÃÖÁ¾ ¿ëµµ ºñÁî´Ï½º ºÐ¼®

Á¦8Àå Áö¿ª ºñÁî´Ï½º ºÐ¼®

Á¦9Àå °æÀï ±¸µµ

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Point-of-Care Molecular Diagnostics Market Summary

The global point of care molecular diagnostics market size was estimated at USD 8.22 billion in 2024 and is projected to reach USD 14.47 billion by 2033, growing at a CAGR of 6.52% from 2025 to 2033. This market focuses on rapid and accurate molecular testing conducted near the patient, enabling timely clinical decision-making. These platforms are used across various applications, particularly in infectious disease detection, respiratory illnesses, and sexually transmitted infections.

Market growth is driven by the rising demand for decentralized testing, especially in resource-limited settings and emergency care environments. The increasing burden of infectious diseases and the need for rapid turnaround time have expanded the adoption of point-of-care molecular technologies. Technological advances in microfluidics, isothermal amplification, and portable PCR systems are enhancing the accuracy and usability of these diagnostics. In addition, post-pandemic healthcare priorities emphasize rapid response testing, further supporting market expansion.

Moreover, POC molecular diagnostics in primary care settings range from simple glucose testing to complex coagulation testing. In several clinics, professionals are switching to POC testing from conventional lab testing, which helps shorten the time taken to decide whether further tests are required by avoiding delays during specimen preparation and transport. Other advantages of POC molecular diagnostics are rapid availability of results, lower costs, and better outcomes. The point of care molecular diagnostics industry has grown rapidly in the past few years, especially in the U.S. and European countries, owing to increased awareness regarding various issues such as medical & organizational concerns and economic advantages of POCT.

Aging is influenced by the interaction of several environmental and genetic factors and is characterized as the single most substantial risk factor for cancer development. Based on the U.S. National Cancer Institute's Surveillance Epidemiology and End Results (SEER) Database, 38% of women and 43% of men are estimated to develop cancer during their lifetime. Nearly two-thirds of all new cancer cases are diagnosed in people aged 65 and above, which highlights that aging can make people more vulnerable to cancer. This is where molecular diagnostics play an important role, as it has a tremendous impact on the management of cancer, infectious diseases, and cardiovascular diseases. It is, therefore, vital for public health surveillance and detection. Thus, the growing geriatric population is expected to drive market growth.

Moreover, market players are continuously involved in the development of novel POC testing products to capitalize on market opportunities. For instance, in February 2023, Huwel Lifesciences designed a portable RT-PCR machine to test types of viruses. The company claimed that the test takes around 30 minutes and can be used to detect respiratory and other infections using blood and gastrointestinal samples. Moreover, in April 2023, Curative, Inc. announced the spin-off of Sensible Diagnostics, focusing on the commercialization of a novel POC PCR testing platform to provide results within 10 minutes with high accuracy.

Global Point Of Care Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global point of care molecular diagnostics market report based on application, technology, test location, end-use, and region:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Technology Business Analysis

Chapter 5. Application Business Analysis

Chapter 6. Test Location Business Analysis

Chapter 7. End Use Business Analysis

Chapter 8. Regional Business Analysis

Chapter 9. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â